Cardinal Health Builds On Generic Device Strategy With Cordis Deal
This article was originally published in The Gray Sheet
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
You may also be interested in...
In this earnings review, we pick out the high achievers and underperformers from the companies that released quarterly results in the past week. Reports from J&J, ResMed, bioMérieux, St. Jude Medical and more.
The $1 billion vascular closure market is primed for growth. It comes on the back of intensive R&D that has spawned a range of alternatives to the traditional manual/compression approach, giving SJM and the sector’s other heavyweights cause to look over their shoulders.
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.